Ingavirin

DRUG3 trials

Sponsors

Valenta Pharm JSC

Conditions

Acute Respiratory InfectionCommon ColdInfluenza, HumanViral Infection

Phase 3

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Children 7-12 y.o.

CompletedNCT03191097

Valenta Pharm JSCAcute Respiratory Infection, Common Cold, Influenza, Human +1

Start: 2014-08-31End: 2015-03-31Updated: 2017-06-19

Efficacy and Safety Study of Ingavirin® to Treat Influenza and Acute Respiratory Viral Infections in Patients 13-17 y.o.

CompletedNCT03206346

Valenta Pharm JSCAcute Respiratory Infection, Common Cold, Influenza, Human +1

Start: 2012-01-31End: 2013-08-31Updated: 2017-07-02

Phase 4

Efficacy and Safety Study of Ingavirin® 90 mg Once Daily to Treat Influenza and Other Acute Viral Infections in Adults

CompletedNCT03154515

Valenta Pharm JSCAcute Respiratory Infection, Common Cold, Influenza, Human

Start: 2010-01-31End: 2014-10-31Updated: 2017-05-16